Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Royalty Pharma plc - Class A Ordinary Shares (NQ: RPRX )

32.36 -0.10 (-0.31%)
Streaming Delayed Price Updated: 4:00 PM EST, Feb 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Royalty Pharma plc - Class A Ordinary Shares

< Previous 1 2 3 4 5 6 7 8 Next >
Royalty Pharma Reports First Quarter 2024 Results
From Royalty Pharma plc
Via GlobeNewswire
Royalty Pharma to Acquire Royalty Interest in Sanofi’s Frexalimab
From Royalty Pharma plc
Via GlobeNewswire
Amgen Reports Better-Than-Expected Q1 Results, $50M Milestone Payment
Amgen reported quarterly earnings of $3.96 per share which beat the analyst consensus estimate of $3.87 by 2.33%. The company said EPS decreased by 1% due to higher operating and interest expenses... 
Via Benzinga
NASDAQ:RPRX: good value for what you're paying.
Investors should take notice ofROYALTY PHARMA PLC- CL A (NASDAQ:RPRX)—it offers a great deal for the fundamentals it presents. 
Via Chartmill
Looking Into Royalty Pharma's Recent Short Interest
Via Benzinga
NASDAQ:RPRX is an undervalued gem with solid fundamentals.
ROYALTY PHARMA PLC- CL A (NASDAQ:RPRX), an undervalued stock with good fundamentals. 
Via Chartmill
Earnings Scheduled For February 15, 2024
Companies Reporting Before The Bell • Cognex (NASDAQ:CGNX) is estimated to report quarterly earnings at $0.10 per share on revenue of $188.59 million. 
Via Benzinga
Royalty Pharma's Earnings: A Preview
Via Benzinga
Royalty Pharma to Announce First Quarter 2024 Financial Results on May 9, 2024
From Royalty Pharma plc
Via GlobeNewswire
Royalty Pharma Declares Second Quarter 2024 Dividend
From Royalty Pharma plc
Via GlobeNewswire
3 Pharma Stocks to Sell in April Before They Crash & Burn
Discover three pharma stocks to sell in April, facing challenges and signaling potential for significant downside. 
Via InvestorPlace
Billionaire Bargain Bin: 3 Stocks the Forbes 400 Loves (That You’ve Never Heard Of)
These Forbes 400 stocks have wealthy founders who run them with little fanfare or attention but are worth considering for your portfolio. 
Via InvestorPlace
NASDAQ:RPRX is an undervalued gem with solid fundamentals.
Despite its impressive fundamentals, ROYALTY PHARMA PLC- CL A (NASDAQ:RPRX) remains undervalued. 
Via Chartmill
NASDAQ:RPRX: good value for what you're paying.
Despite its impressive fundamentals, ROYALTY PHARMA PLC- CL A (NASDAQ:RPRX) remains undervalued. 
Via Chartmill
April’s Hidden Gems: 3 Overlooked Stocks to Freshen Up Your Portfolio
Discover three overlooked stocks on Wall Street with the potential for growth and diversification this April. 
Via InvestorPlace
The Healthcare Bargain Blitz: 7 Undervalued Stocks to Inject into Your Portfolio
With a possible rotation away from the technology space, these are the undervalued healthcare stocks to consider. 
Via InvestorPlace
For those who appreciate value investing, NASDAQ:RPRX is a compelling option with its solid fundamentals.
When you look at ROYALTY PHARMA PLC- CL A (NASDAQ:RPRX), it's hard to ignore the strong fundamentals, especially considering its likely undervaluation. 
Via Chartmill
Royalty Pharma to Present at TD Cowen’s 44th Annual Health Care Conference
From Royalty Pharma plc
Via GlobeNewswire
Wall Street Thinks These 3 Stocks Are Hidden Gems That Could Soar 43% to 59% Over the Next 12 Months
Analysts are quite bullish about these beaten-down stocks. 
Via The Motley Fool
Royalty Pharma Reports Q4 and Full Year 2023 Results
From Royalty Pharma plc
Via GlobeNewswire
3 Biotech Stocks to Buy for the Next Bull Run: February 2024
These are the biotech stocks to buy that you must have on your watchlist for the coming bull run. It could get started as soon as this month. 
Via InvestorPlace
NASDAQ:RPRX is a prime example of a stock that offers more than what meets the eye in terms of fundamentals.
ROYALTY PHARMA PLC- CL A (NASDAQ:RPRX) is an undervalued gem with solid fundamentals. 
Via Chartmill
How Risky Is Royalty Pharma’s Dividend?
Royalty Pharma just announced a 5% dividend increase, its fourth raise in a row. It has boosted the dividend every year since it began paying one in 2020. The new $0.21 per share quarterly dividend... 
Via Talk Markets
Royalty Pharma To Announce Fourth Quarter And Full Year 2023 Financial Results On February 15, 2024
From Royalty Pharma plc
Via GlobeNewswire
Top Stocks That Just Increased Their Dividends
There are several reasons why investors tend to favor stocks that have had a dividend increase. 
Via Talk Markets
Royalty Pharma Announces Dividend Increase
From Royalty Pharma plc
Via GlobeNewswire
NASDAQ:RPRX appears to be flying under the radar despite its strong fundamentals.
ROYALTY PHARMA PLC- CL A (NASDAQ:RPRX) is an undervalued gem with solid fundamentals. 
Via Chartmill
Royalty Pharma Highlights Accomplishments and Provides Business Update at 42nd Annual J.P. Morgan Healthcare Conference
From Royalty Pharma plc
Via GlobeNewswire
NASDAQ:RPRX is a prime example of a stock that offers more than what meets the eye in terms of fundamentals.
ROYALTY PHARMA PLC- CL A (NASDAQ:RPRX) is probably undervalued for the fundamentals it is displaying. 
Via Chartmill
Royalty Pharma to Present at the Evercore ISI 6th Annual HealthCONx Conference
From Royalty Pharma plc
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.